Bexionpharma

1 known investors

Bexion Pharmaceuticals develops BXQ-350, a biologic therapy that targets sphingolipid metabolism to enhance cancer cell death and improve the effectiveness of standard therapies in patients with advanced solid tumors, particularly metastatic colorectal cancer.

BiotechMedical Devices